Skip To Main Content
Dexter Yan on Muck Rack

Dexter Yan

Verified
Shanghai Shi
As seen in: Citeline, Scrip, The Pink Sheet, Generics Bulletin, In Vivo, Medtech Insight, In Vivo Podcasts
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dexter

Contact Dexter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Chinese Rivals To Revolution’s Rasonque Line Up In The Clinic

|
By Dexter Yan Verified
| Scrip Verified
A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October. Chinese pan-RAS inhibitors are fast-following Revolution’s Rasonque.
Open in Who Shared Issue with article?

New Standard Of Care As Ivonescimab Bests Imfinzi In 1L Biliary Tract Cancer?

|
By Dexter Yan Verified
| Scrip Verified
Akeso’s ivonescimab plus chemo beats Imfinzi plus chemo in overall survival terms in head-to-head Phase III trial in untreated biliary tract cancer. Akeso’s ivonescimab, an anti-PD-1 x VEGF bispecific antibody, has bested AstraZeneca’s PD-L1-targeting antibody Imfinzi (durvalumab) in a China-only, head-to-head Phase III trial, where the biologics were evaluated in combination with doublet chemotherapy for first-line biliary tract cancer (BTC).
Open in Who Shared Issue with article?

Deal Watch: Chai Will Seek Novel Antibodies For BMS In Its Latest AI Discovery Alliance

|
By Joseph Haas Verified, Lisa Takagi Verified, Dexter Yan Verified
| Scrip Verified
Plus deals involving Fulcrum/Slate, Oblenio/Leads Biolabs, GSK/Chugai, IASO/MediSix, Innate/SOBI and more.
Open in Who Shared Issue with article?
See all 604 articles